The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2024 | Daratumumab in the treatment of heavily pretreated immune-mediated TTP
Júlia Weisinger, MD, Hospital Saint-Antoine AP-HP, Paris, France, discusses the safety and efficacy of daratumumab in immune-mediated thrombotic thrombocytopenic purpura (TTP), a rare and challenging-to-study disease. The study included heavily pretreated patients who were refractory to therapies such as rituximab. Daratumumab was effective in this population, leading to significant restoration of normal ADAMTS13 activity in many patients. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
